Requiring a system that would be intuitive and easy-to-use for museum visitors, while also demonstrating how innovation can impact our lives, ICER selected FST Biometrics to provide its award-winning IMID
In a statement, FST Biometrics Product Manager Ilan Krugliak stated that the upgrade demonstrates our conviction that advanced security systems should work for the user, and not the other way around, adding that besides improving the user experience the increased capabilities of IMID
Realizing FST Biometrics' vision of providing secure access that does not interfere with the pace of life, IMID
FST was selected after completing a rigorous trial period, in which the company's IMID
Access successfully passed all testing, and was subsequently piloted at the world-renowned International Diamond Week, hosted by the IDE in April 2014.
Mobile, a smartphone application, is designed to identify visitors on a mobile device and enhance the important work of security personnel by providing them with valuable supplemental information about visitors to sites in need of tight security.
The implementation of FST Biometrics' newly-released IMID
Mobile solution with Hagana Security demonstrates a key application of our secure access capabilities," said Arie Melamed Yekel , CMO of FST Biometrics.
Mobile is a smartphone application that delivers FST's award-winning IMID
technology to personal devices, while IMID
Rapid provides an end-to-end, ruggedized and portable solution to quickly secure access to contained areas, such as crime scenes and senior government official press conferences.
, now in its fourth year, allows people to view all the latest trends in the global display industry.
These high-level discussions included Shigeo Mikoshiba, SID's president, and Sang Wan Lee, chairman of the Korean Information Display Society (KIDS), which co-hosts IMID
with SID this year.
Access system, provided by award-winning secure access technology provider FST Biometrics, utilizes a fusion of biometrics information.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Pomalidomide and other IMiDs continue to be evaluated in over 100 clinical trials.